title: EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin).
abstract: BACKGROUND
  In January 2004, EMEA approved 90Y-radiolabelled ibritumomab tiuxetan, Zevalin, in Europe for the treatment of adult patients with rituximab-relapsed or -refractory CD20+ follicular B-cell non-Hodgkin's lymphoma. The number of European nuclear medicine departments using Zevalin is continuously increasing, since the therapy is often considered successful. The Therapy, Oncology and Dosimetry Committees have worked together in order to define some EANM guidelines on the use of Zevalin, paying particular attention to the problems related to nuclear medicine.
  
  
  OBJECTIVE
  The purpose of this guideline is to assist the nuclear medicine physician in treating and managing patients who may be candidates for radio-immunotherapy. The guideline also stresses the need for close collaboration with the physician(s) treating the patient for the underlying disease.
authors.affiliation: Department of Oncology, Lund University Hospital, 221 85, Lund, Sweden. Jan.Tennvall@med.lu.se
authors.forename: Jan
authors.initials: J
authors.lastname: Tennvall
authors.forename: Manfred
authors.initials: M
authors.lastname: Fischer
authors.forename: Angelika
authors.initials: A
authors.lastname: Bischof Delaloye
authors.forename: Emilio
authors.initials: E
authors.lastname: Bombardieri
authors.forename: Lisa
authors.initials: L
authors.lastname: Bodei
authors.forename: Francesco
authors.initials: F
authors.lastname: Giammarile
authors.forename: Michael
authors.initials: M
authors.lastname: Lassmann
authors.forename: Wim
authors.initials: W
authors.lastname: Oyen
authors.forename: Boudewijn
authors.initials: B
authors.lastname: Brans
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D006801:Humans; D016393:Lymphoma, B-Cell / Q000532:radiotherapy*; D009683:Nuclear Medicine / Q000592:standards*; D010818:Practice Patterns, Physicians' / Q000592:standards; D016499:Radioimmunotherapy / Q000592:standards*; D019275:Radiopharmaceuticals / Q000592:standards / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D019275:Radiopharmaceuticals; C422802:ibritumomab tiuxetan